We’re at the forefront of a revolutionary approach to inflammatory bowel disease (IBD) treatment, tackling major unmet needs by focusing on mucosal healing and personalized care.
Our innovative reverse translational approach harnesses the power of multimodal patient data and analytics to develop cutting-edge diagnostics and therapeutics. We’re not just treating IBD; we’re redefining its management through precision medicine, tailoring solutions to each patient’s unique biological fingerprint.
Addressing Unmet Needs in IBD
IBD affects over 6 million people worldwide, including 3 million Americans. This chronic condition, encompassing both Ulcerative Colitis and Crohn’s Disease, presents significant challenges for patients and healthcare systems alike.
- Limited Treatment Success: Despite available therapies, only 20-30% of patients achieve long-term remission. The high rate of treatment failure leads to increased hospitalizations, complications, and healthcare costs.
- Need for Precision Medicine: IBD manifests differently in each patient, yet current treatments follow a one-size-fits-all approach. The field urgently needs tools to match patients with the most effective therapies from the start, eliminating costly trial-and-error approaches.
- Beyond Inflammation: While existing treatments primarily target inflammation, they often fall short in promoting tissue repair. There’s a critical need for therapies that can restore the intestinal barrier and modify disease progression.
What Makes Mobius Different?
First-of-its kind, AI-powered, H&E image-based predictive biomarker of response
First-of-its kind, AI-powered, H&E image-based predictive biomarker of response
- Treatment response prediction to existing IBD therapies from standard of care H&E images, dramatically improving treatment response rates by matching the right treatment for the right patient
- Clinical trials optimization for new IBD therapies by identifying patients likely to achieve spontaneous remission
- Without requiring additional sampling, or complex laboratory processing. Fits well in current clinical workflow
Pioneering Therapeutic Strategy Beyond Immune Suppression
Pioneering Therapeutic Strategy Beyond Immune Suppression
- Unique mechanisms of action: Our therapies target specific cellular and microbial factors that hinder mucosal healing, offering a complementary approach to existing immunomodulatory treatments.
- Unlike 90% of existing drugs that focus solely on immune system suppression, our innovative approach addresses the root causes of IBD:
- Targeting microbial dysbiosis
- Targeting a key protein to promote mucosal repair
- Designed as combination therapies to enhance existing treatments
Scientifically Validated, Data-Driven Approach
Scientifically Validated, Data-Driven Approach
- Deeply rooted in rigorous scientific research led by world-renowned IBD researcher Dr. Thaddeus Stappenbeck
- Discoveries derived directly from comprehensive patient data analysis
- Leveraging our sophisticated reverse translational research model that transforms clinical insights into targeted therapies
Featured News
Mobius Care Receives Funding from Crohn’s & Colitis Foundation to Advance AI-Powered Precision Medicine for Inflammatory Bowel Disease (IBD)
Mobius Care, a Cleveland Clinic-founded company that is pioneering a new approach to precision medicine for patients with Inflammatory Bowel Disease (IBD), today announced it has received funding from the Crohn’s & Colitis Foundation. The Foundation is a non-profit organization committed to finding cures for Crohn’s disease and ulcerative colitis.
Partners and Collaborators
